Arcturus Therapeutics Holdings Inc ARCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
-
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
-
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
-
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
-
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
-
Arcturus Therapeutics Shares Rise on Plans to Work with Thermo Fisher Scientific on Cystic Fibrosis Drug
Trading Information
- Previous Close Price
- $9.91
- Day Range
- $9.80–11.50
- 52-Week Range
- $5.50–17.96
- Bid/Ask
- $11.24 / $12.90
- Shares Outstanding
- 28.42M
- Market Cap
- $319.19M
- Volume/Avg
- 200 / 942,192
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 111
- Website
- https://www.arcturusrx.com
Valuation
|
Metric
|
ARCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.86 |
Price/Sales | 16.82 |
Price/Cash Flow | — |
Price/Earnings
ARCT
Financial Strength
|
Metric
|
ARCT
|
|---|---|
Quick Ratio | 5.76 |
Current Ratio | 5.88 |
Interest Coverage | — |
Quick Ratio
ARCT
Profitability
|
Metric
|
ARCT
|
|---|---|
Return on Assets (Normalized) | −26.99% |
Return on Equity (Normalized) | −34.83% |
Return on Invested Capital (Normalized) | −34.74% |
Return on Assets
ARCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%?#@zTC | LOCK|?w#l? | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|F@mHFW | LOCK|QY!W@ | $84B | |||
| Moderna Inc
MRNA
| LOCK|f<nJf! | LOCK|$y | $83B | |||
| argenx SE ADR
ARGX
| LOCK|D?%@r$ | LOCK|&G# | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#@?JVqN | LOCK|p@ | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bK^$nqG | LOCK|>DrN | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|BCS?<Q#^ | LOCK|gy<K< | $29B | |||
| Incyte Corp
INCY
| LOCK|tqQrNzH | LOCK|WX | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|$gsD^$? | LOCK|?w> | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%Nv$fGY | LOCK|vsG | $14B |
United States